Monosialoganglioside

also known as GM1

Developed for: ischemic stroke · poisoning
Investigated by: Beijing Shijitan Hospital, Capital Medical University · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Chinese PLA General Hospital · Peking Union Medical College Hospital · Peking University Cancer Hospital & Institute · Peking University First Hospital
+4 more
· Peking University Third Hospital · Qilu Pharmaceutical Co., Ltd. · Weifang People's Hospital · Yantai Yuhuangding Hospital

today NCT06742216 · Ph 3 NCT02500810 · Ph 2

201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT02500810	Jul 2015 → Jul 2018	poisoning	Peking University Cancer Hospital & Institute	Unknown	No outcome recorded
Phase 31 trial
Phase 3	NCT06742216	Nov 2020 → Aug 2023	ischemic stroke	Qilu Pharmaceutical Co., Ltd.	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	monosialoganglioside	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02500810 ↗ 1 NCT06742216 ↗
Known as	GM1	“Monosialoganglioside GM1, 200 mg/day, for 12-14 days” NCT06742216 ↗
Route	Intravenous	“40mg in the vein on day 1 - day 8 of each 21 days cycle.” NCT02500810 ↗